Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Genetics

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 40 articles: HTML format

Single Articles

November 2025
1. LOKMAN NA, Macpherson AM, Thompson AR, Price ZK, et al
   Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer.
   Br J Cancer. 2025 Nov 5. doi: 10.1038/s41416-025-03244.
   PubMed     Abstract available
   
   
   October 2025
2. WU WZ, Huang HC, Zhu GH, Liao LD, et al
   Serum multiomics prediction of prognosis and adverse reactions to concurrent chemoradiotherapy in patients with esophageal cancer.
   Br J Cancer. 2025 Oct 8. doi: 10.1038/s41416-025-03229.
   PubMed     Abstract available
   
   
   September 2025
3. GIL JV, Avetisyan G, Miralles A, de Las Heras S, et al
   Benchmarking standard-of-care and emerging genomic approaches to enhance diagnosis in pediatric acute lymphoblastic leukemia.
   Br J Cancer. 2025 Sep 30. doi: 10.1038/s41416-025-03204.
   PubMed     Abstract available
   
   
   
4. MONTERO-CALLE A, Jimenez de Ocana S, Rejas-Gonzalez R, Benavente-Naranjo R, et al
   Deciphering the central role of TMOD2 in colorectal cancer progression and metastasis.
   Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03184.
   PubMed     Abstract available
   
   
   
5. STEGGALL J, Rajeeve V, Al-Subaie N, Naeem A, et al
   Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer.
   Br J Cancer. 2025 Sep 13. doi: 10.1038/s41416-025-03174.
   PubMed     Abstract available
   
   
   
6. LI Y, Yuan X, Yin XF, Zheng D, et al
   Proteomics analysis and immune profiling reveal regulators of PD-L1 in oesophageal squamous cell carcinoma.
   Br J Cancer. 2025;133:448-463.
   PubMed     Abstract available
   
   
   
7. LAN Z, Yang Y, Li L, Wang C, et al
   Spatial omics technology potentially promotes the progress of tumor immunotherapy.
   Br J Cancer. 2025;133:421-434.
   PubMed     Abstract available
   
   
   
8. YANG X, Sun L, Guo J, Zheng Y, et al
   Deciphering the role of IGF2BP2 and PRMT5 in gallbladder cancer progression: insights from multi-omics analysis.
   Br J Cancer. 2025;133:486-507.
   PubMed     Abstract available
   
   
   August 2025
9. ROCCA A, Crino L, Braga L, Salton F, et al
   Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies.
   Br J Cancer. 2025 Aug 23. doi: 10.1038/s41416-025-03139.
   PubMed     Abstract available
   
   
   June 2025
10. BARRAUD S, Vacher S, Schiffler C, Wong J, et al
    Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03083.
    PubMed     Abstract available
    
    
    
11. HUANG C, Qiu Z, Huang H, Xiao X, et al
    Alterations in genomic features and the tumour immune microenvironment predict immunotherapy outcomes in advanced biliary tract cancer patients.
    Br J Cancer. 2025;132:1072-1082.
    PubMed     Abstract available
    
    
    March 2025
12. LEE HJ, Park SW, Lee JH, Chang SY, et al
    Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes.
    Br J Cancer. 2025 Mar 3. doi: 10.1038/s41416-025-02964.
    PubMed     Abstract available
    
    
    December 2024
13. LEUNG EYL, Robbins HL, Zaman S, Lal N, et al
    The potential clinical utility of Whole Genome Sequencing for patients with cancer: evaluation of a regional implementation of the 100,000 Genomes Project.
    Br J Cancer. 2024;131:1805-1813.
    PubMed     Abstract available
    
    
    November 2024
14. TAN R, Wen M, Yang W, Zhan D, et al
    Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets.
    Br J Cancer. 2024 Nov 15. doi: 10.1038/s41416-024-02894.
    PubMed     Abstract available
    
    
    
15. KAUFMANN M, Vaysse PM, Savage A, Kooreman LFS, et al
    Testing of rapid evaporative mass spectrometry for histological tissue classification and molecular diagnostics in a multi-site study.
    Br J Cancer. 2024;131:1298-1308.
    PubMed     Abstract available
    
    
    
16. TORR B, Jones C, Kavanaugh G, Hamill M, et al
    BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial.
    Br J Cancer. 2024;131:1506-1515.
    PubMed     Abstract available
    
    
    October 2024
17. SHEN M, Garcia-Marques F, Muruganantham A, Liu S, et al
    Identification of a 5-gene signature panel for the prediction of prostate cancer progression.
    Br J Cancer. 2024 Oct 14. doi: 10.1038/s41416-024-02854.
    PubMed     Abstract available
    
    
    August 2024
18. NAGELBERG AL, Sihota TS, Chuang YC, Shi R, et al
    Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response.
    Br J Cancer. 2024;131:534-550.
    PubMed     Abstract available
    
    
    July 2024
19. ANGERILLI V, Sabella G, Simbolo M, Lagano V, et al
    Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
    Br J Cancer. 2024;131:159-170.
    PubMed     Abstract available
    
    
    
20. VALOUS NA, Popp F, Zornig I, Jager D, et al
    Graph machine learning for integrated multi-omics analysis.
    Br J Cancer. 2024;131:205-211.
    PubMed     Abstract available
    
    
    June 2024
21. TSOULAKI O, Tischkowitz M, Antoniou AC, Musgrave H, et al
    Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.
    Br J Cancer. 2024;130:2027-2036.
    PubMed     Abstract available
    
    
    May 2024
22. MENG XN, Ma JF, Liu YH, Li SQ, et al
    Dynamic genomic changes in methotrexate-resistant human cancer cell lines beyond DHFR amplification suggest potential new targets for preventing drug resistance.
    Br J Cancer. 2024;130:1819-1827.
    PubMed     Abstract available
    
    
    April 2024
23. DHAR C, Ramachandran P, Xu G, Pickering C, et al
    Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
    Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02644.
    PubMed     Abstract available
    
    
    March 2024
24. FELIU J, Gamez-Pozo A, Martinez-Perez D, Perez-Wert P, et al
    Functional proteomics of colon cancer Consensus Molecular Subtypes.
    Br J Cancer. 2024 Mar 14. doi: 10.1038/s41416-024-02650.
    PubMed     Abstract available
    
    
    February 2024
25. PRETE AA, Angerilli V, Bergamo F, Vettore V, et al
    HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-023-02569.
    PubMed     Abstract available
    
    
    January 2024
26. WANG Y, He M, He T, Ouyang X, et al
    Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers.
    Br J Cancer. 2024 Jan 22. doi: 10.1038/s41416-023-02555.
    PubMed     Abstract available
    
    
    
27. HALLAL SM, Tuzesi A, Sida LA, Xian E, et al
    Glioblastoma biomarkers in urinary extracellular vesicles reveal the potential for a 'liquid gold' biopsy.
    Br J Cancer. 2024 Jan 11. doi: 10.1038/s41416-023-02548.
    PubMed     Abstract available
    
    
    December 2023
28. GRASSMANN F, Malarstig A, Dahl L, Bendes A, et al
    The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk.
    Br J Cancer. 2023 Dec 22. doi: 10.1038/s41416-023-02541.
    PubMed     Abstract available
    
    
    September 2023
29. PAYNE K, Brooks J, Batis N, Khan N, et al
    Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping.
    Br J Cancer. 2023 Sep 21. doi: 10.1038/s41416-023-02428.
    PubMed     Abstract available
    
    
    
30. YANG Y, Xu S, Jia G, Yuan F, et al
    Integrating genomics and proteomics data to identify candidate plasma biomarkers for lung cancer risk among European descendants.
    Br J Cancer. 2023 Sep 7. doi: 10.1038/s41416-023-02419.
    PubMed     Abstract available
    
    
    
31. LIU Z, Duan T, Zhang Y, Weng S, et al
    Radiogenomics: a key component of precision cancer medicine.
    Br J Cancer. 2023;129:741-753.
    PubMed     Abstract available
    
    
    August 2023
32. VAN MOURIK A, Tonkin-Hill G, O'Farrell J, Waller S, et al
    Six-year experience of Australia's first dedicated cancer of unknown primary clinic.
    Br J Cancer. 2023;129:301-308.
    PubMed     Abstract available
    
    
    July 2023
33. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
    Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
    PubMed     Abstract available
    
    
    June 2023
34. XU L, Su H, Zhao S, Si H, et al
    Development of the semi-dry dot-blot method for intraoperative detecting micropapillary component in lung adenocarcinoma based on proteomics analysis.
    Br J Cancer. 2023;128:2116-2125.
    PubMed     Abstract available
    
    
    
35. KITAGAWA A, Osawa T, Noda M, Kobayashi Y, et al
    Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma.
    Br J Cancer. 2023;128:2206-2217.
    PubMed     Abstract available
    
    
    May 2023
36. RASMUSSEN SV, Wozniak A, Lathara M, Goldenberg JM, et al
    Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcoma.
    Br J Cancer. 2023;128:1941-1954.
    PubMed     Abstract available
    
    
    April 2023
37. ROSSWOG C, Fassunke J, Ernst A, Schomig-Markiefka B, et al
    Genomic ALK alterations in primary and relapsed neuroblastoma.
    Br J Cancer. 2023;128:1559-1571.
    PubMed     Abstract available
    
    
    March 2023
38. CIFUENTES GA, Santiago A, Mendez Blanco L, Fueyo M, et al
    Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy.
    Br J Cancer. 2023;128:857-876.
    PubMed     Abstract available
    
    
    February 2023
39. NJOKU K, Pierce A, Geary B, Campbell AE, et al
    Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women.
    Br J Cancer. 2023 Feb 17. doi: 10.1038/s41416-022-02139.
    PubMed     Abstract available
    
    
    
40. CHEN G, Zhang J, Fu Q, Taly V, et al
    Integrative analysis of multi-omics data for liquid biopsy.
    Br J Cancer. 2023;128:505-518.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Genetics is free of charge.